Pharma Biotech

The deep-tech founder leveraging AI to address challenges in immunology

Camille Bouget discusses how artificial intelligence is impacting innovation in the treatment of diseases affecting the immune system. Read more: The deep-tech founder leveraging AI to address challenges in immunology

AI-led selloff in contract research firms may be misjudging disruption risk

The AI-led selloff in contract research firms may be misjudging disruption risk.

Eli Lilly signs $2bn deal for AI drug development with Hong Kong biotech

Global pharmaceutical companies are aggressively searching for new medicines in China

Eli Lilly strikes $2.75B deal for AI drug development

We cannot provide a description for this page right now

Eli Lilly Partners with Insilico Medicine

Eli Lilly partners with Insilico Medicine in a $2.75 billion deal, securing AI-driven drug discovery capabilities to enhance R&D efficiency.

Lab-grown neurons say "Hello, World!" — and attract new investment

Salt Lake City startup Intactis Bio Corp, backed by a new $250,000 investment from Nucleus Fund, has demonstrated living neurons performing math and language tasks — a key milestone toward ultra-efficient, biologically powered AI computing.

Petasight Acquires Babbage Insight for AI-Led Operations

Petasight Inc. has acquired Babbage Insight Two Inc. to enhance its AI-led operating system for life sciences PMR.

Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science Startups

Breakout Ventures has announced the close of its $114 million Fund III, marking a new phase of investment focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence. The post Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science Startups appeared first on Pulse 2.0.

Ternary Therapeutics Raises €4.1M for AI-Powered Drug Discovery Platform

Ternary Therapeutics, a London-based biotechnology company, has raised €4. 1 million (£3. 6 million) in a seed funding round to enhance its AI-powered platform for drug discovery.

Vst Bio Raises $45M for AI-Powered Stroke Therapy

Vst bio, a biotechnology company focused on vascular diseases, has closed a $45 million Series A financing round to advance its lead stroke therapy candidate, vb-001. The round was led by Coefficient Giving, a philanthropic funder dedicated to impactful scientific research.

Sequential Raises $3.5M to Enhance AI-Powered Skin Microbiome Discovery

Sequential, a genomic testing company specializing in non-invasive human clinical samples, has raised $3. 5 million in its first equity funding round, increasing its total funding to $7. 5 million.

Persistent Systems and NVIDIA Unite to Revolutionize AI-Driven Drug Discovery

Persistent Systems partners with NVIDIA to enhance AI-driven drug discovery, using NVIDIA's AI platform for more efficient healthcare and life sciences solutions.

Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million

London-based BioTech startup Ternary Therapeutics has raised €4. 1 million (£3. 6 million) in Seed funding to scale an AI platform designed to create a new class of medicines known as molecular glues.

AI-Powered mRNA Vaccine Shrinks Tumor

A rescue dog with cancer saw significant tumor reduction after receiving an AI-designed personalized mRNA vaccine. Though promising, experts urge caution due to regulatory and ethical concerns in AI-assisted medical treatments.

AI Used to Help Dying Dog

A tech entrepreneur used AI to help prolong the life of his dying dog. Read the full profile to learn more about this heartwarming story.

Pharma Giants Invest in AI

Leading pharmaceutical companies and biotech firms are heavily investing in AI platforms to revolutionize drug discovery and development.

ELISA: An Interpretable Hybrid Generative AI Agent for Expression-Grounded Discovery in Single-Cell Genomics

Translating single-cell RNA sequencing (scRNA-seq) data into mechanistic biological hypotheses remains a critical bottleneck, as agentic AI systems lack direct access to transcriptomic representations while expression foundation models remain opaque to natural language. Here we introduce ELISA (Embedding-Linked Interactive Single-cell Agent), an interpretable framework that unifies scGPT expression embeddings with BioBERT-based semantic retrieval and LLM-mediated interpretation for interactive s...

First Multi-Behavior Brain Upload

Eon Systems is framing its work as an early whole-brain emulation milestone, building on the fruit fly connectome research that mapped roughly 139,255 neurons and 50 million synaptic connections and on executable fly-brain models that researchers say can help study multiple interacting neural circuits. This is intellectually striking as a possible long-term path beyond today's LLM paradigm, but the immediate business implications remain speculative and the work is much more relevant to neuroscience and basic research than near-term enterprise deployment.

Large Genome Model: Open Source AI Trained on Trillions of Bases

A large genome model is an open source AI trained on trillions of bases.

Liquid AI and Insilico Medicine Partnership

Liquid AI and Insilico Medicine have announced a strategic partnership targeting AI in healthcare and drug discovery. The partnership aims to develop lightweight scientific foundation models that can run on internal compute and be tuned to proprietary biomedical data. This partnership is seen as an early example of the 'small, domain-specific models' trend and a reminder that owning AI capabilities behind the firewall can matter for competitive differentiation.

Antiverse Secures $9.3M to Expand AI Antibody Design Platform

Antiverse has raised $9.3 million in a Series A funding round to enhance its AI-driven antibody design platform and expand its therapeutic pipeline.

GenomeOcean Revolutionizes Genomic Data with AI

GenomeOcean, a JGI initiative, leverages large language models to accelerate genomic research by drastically reducing model training times, aiming for a 30–350 times improvement. With the upcoming Doudna supercomputer and collaborations with NVIDIA and Dell, GenomeOcean emphasizes open science and AI enablement to streamline genomic data processing and enhance precision medicine and environmental research.

r/bioinformatics on Reddit: Every day that I choose AI makes me feel like I'm digging my own grave

I'd say if you ask most good comp scientists how they feel about Claude code they are glad that they don't have to do as much scut coding and can focus on the fun parts of the job like project design and biological interpretation, which Claude sucks at as it has no biological intuition. Just remember, AI manipulates representations of knowledge, it does not interpret reality itself.

I think you are right on people's general misunderstanding of LLMs doing magical drug discovery discovery. But I think one of the goals is to have AI act as a generalist scientist doing experiments like a human would, but scaled. Not there yet, but real progress from Google.

I think you are right on people's general misunderstanding of LLMs doing magical drug discovery discovery. But I think one of the goals is to have AI act as a generalist scientist doing experiments like a human would, but scaled. Not there yet, but real progress from Google.

AI to Help Researchers See the Bigger Picture in Cell Biology

An AI-driven method can provide holistic information on a cell, helping scientists better understand disease mechanisms and plan experiments.

Pfizer Unveils Second AI-Driven Lab

Pfizer and Telescope Innovations have completed the installation of a second Self-Driving Laboratory (SDL), accelerating drug development with AI-guided experimentation and robotics. This move marks a significant step towards full-scale deployment, potentially slashing research costs and timelines by up to 100 times, while extending SDL's application beyond pharmaceuticals.

Pfizer Unveils Second AI-Driven Lab to Revolutionize Drug Development and Cut Costs

Pfizer unveils second AI-driven lab to revolutionize drug development and cut costs.

Flinn: $20 Million Raised To Automate The Product Lifecycle In Medtech And Pharma With AI

Flinn raised $20 million to expand AI-powered automation in MedTech and Pharma product lifecycles, focusing on regulatory and quality processes. The funding will accelerate commercialization and market reach. This investment underscores AI's role in streamlining complex industry operations.

'An AlphaFold 4’ – scientists marvel at DeepMind drug spin-off’s exclusive new AI

'An AlphaFold 4’ – scientists marvel at DeepMind drug spin-off’s exclusive new AI

The next frontier in oncology: Why survival must become a designed metric, not a passive outcome

It is no secret by now that technological advances, especially artificial intelligence, have driven profound structural changes in healthcare. From the speed at which clinical tasks are executed to the precision that reduces human error, the industry is experiencing a long-awaited transformation. In oncology, these shifts are even more pronounced.

Pharmacelera Raises €6 Million To Expand In U.S. And Advance Quantum-AI Platform

Pharmacelera, a deep tech company applying Quantum Mechanics and Artificial Intelligence to drug discovery, announced it has closed a €6 million investment round to accelerate its expansion into the United States and further develop its proprietary platform. The post Pharmacelera Raises €6 Million To Expand In U.S. And Advance Quantum-AI Platform appeared first on Pulse 2.0 .

Molecular Design beyond Training Data with Novel Extended Objective Functionals of Generative AI Models Driven by Quantum Annealing Computer

Deep generative modeling to stochastically design small molecules is an emerging technology for accelerating drug discovery and development. However, one major issue in molecular generative models is their lower frequency of drug-like compounds. To resolve this problem, we developed a novel framework for optimization of deep generative models integrated with a D-Wave quantum annealing computer, where our Neural Hash Function (NHF) presented herein is used both as the regularization and binarizat...

Mankind Pharma Optimizes Supply Chain Efficiency

In partnership with Accenture, Mankind Pharma has revamped its global supply chain, achieving a 75% reduction in drug stock-outs and a 20% improvement in inventory optimization. This overhaul bolsters operational resilience and supports sustainable growth, enabling the delivery of affordable medicines amid evolving healthcare demands.

Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation

The scientist using AI to hunt for antibiotics just about everywhere

When he was just a teenager trying to decide what to do with his life, César de la Fuente compiled a list of the world’s biggest problems. He ranked them inversely by how much money governments were spending to solve them. Antimicrobial resistance topped the list.

GPT-5 Slashes Lab Costs at Ginkgo Bioworks

Deployment of GPT-5 in Ginkgo Bioworks' cloud lab has reduced protein production costs by 40% and key lab ingredient expenses by 57% across 36,000 experiments. This application of AI demonstrates substantial cost efficiencies in biotechnology operations. The savings highlight AI's role in optimizing resource use and accelerating research, potentially lowering barriers to entry in biomanufacturing and enhancing profitability for AI-integrated labs.

AI startup Phylo nabs $13.5M for its ‘integrated biology environment’

Biology software developer Phylo Inc. today announced that it has raised $13. 5 million in seed funding.

A comparison of the innovation and regulatory environments for ...

Biotechnology has significant potential to drive economic growth and address major societal challenges, but realising this potential across sectors requires.

Does MannKind Corporation stock benefit from AI growth - Portfolio Return Report & Accurate Intraday Trading Signals

MannKind Corporation's stock is analyzed for potential benefits from AI growth in the pharma and biotech sector. The report suggests opportunities for secure, high returns starting with $100 investments.